ArticleNPJ Parkinson's disease2026
Explainable SHAP- XGBoost with DAT and clinical data for freezing of gait detection in Parkinson disease.
Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Freezing of gait (FOG) is a common and debilitating symptom in Parkinson's disease (PD) that requires early detection for timely intervention. In this study, we developed an explainable SHAP-XGBoost model integrating clinical assessments and dopamine transporter (DAT) imaging to identify L-dopa responsive FOG. The internal cohort included 516 participants, with the model trained on a subset and validated on both internal and external test sets (Parkinson's Progression Markers Initiative, PPMI). The model demonstrated strong predictive performance, achieving AUCs of 0.90, 0.89, and 0.75 on the internal training, internal test, and external PPMI sets, respectively. SHAP analysis revealed that Hoehn & Yahr (H&Y) staging and DAT availability in the contralateral anterior putamen were the most influential features. Threshold analyses identified key cutoffs: around 5 years for disease duration, 64 years for age, and 35.7 for MDS-UPDRS Part III score. Notably, among patients with milder motor symptoms (H&Y ≤ 2.5), a contralateral anterior putamen SBR below 1.25 was associated with a higher FOG risk compared to those with H&Y > 2.5. In summary, our explainable model effectively detects L-dopa responsive FOG by leveraging clinical and DAT imaging data, emphasizing the contralateral anterior putamen as a critical region in FOG pathophysiology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.